Gilead Sciences (GILD) Income from Continuing Operations (2009 - 2026)
Gilead Sciences posted quarterly Income from Continuing Operations of 2021000000.0 for Q1 2026, up 53.69% year-on-year from 1315000000.0 in Q1 2025, and down 20.06% on a QoQ basis from 2528000000.0 in Q4 2025.
Gilead Sciences (GILD) has 18 years of Income from Continuing Operations data on file, last reported at 2021000000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 53.69% year-over-year to 2021000000.0; the trailing twelve-month figure through Mar 2026 stood at 9562000000.0 (up 60.3% YoY), and the FY2025 full-year result was 8510000000.0, up 1676.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2021000000.0, down from 2528000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3052000000.0 in Q3 2025 and bottomed at 4171000000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 1615000000.0 (2024), against an average of 1266647058.82.
- The widest annual swing landed in 2023, when Income from Continuing Operations jumped 8100.0%; it then plunged 523.88% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 1633000000.0 in 2022, then declined by 13.29% to 1416000000.0 in 2023, then climbed by 25.85% to 1782000000.0 in 2024, then jumped by 41.86% to 2528000000.0 in 2025, then declined by 20.06% to 2021000000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2021000000.0 (Q1 2026), 2528000000.0 (Q4 2025), and 3052000000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.53 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 984.00 Mn |
| Dec 31, 2022 | 1.63 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 376.00 Mn |
| Sep 30, 2021 | 2.59 Bn |
| Jun 30, 2021 | 1.52 Bn |
| Mar 31, 2021 | 1.72 Bn |
| Dec 31, 2020 | 1.54 Bn |
| Sep 30, 2020 | 353.00 Mn |
| Jun 30, 2020 | -3.35 Bn |
| Mar 31, 2020 | 1.54 Bn |
| Dec 31, 2019 | 701.00 Mn |
| Sep 30, 2019 | -1.17 Bn |
| Jun 30, 2019 | 1.88 Bn |
| Mar 31, 2019 | 1.97 Bn |
| Dec 31, 2018 | 428.00 Mn |
| Sep 30, 2018 | 2.10 Bn |
| Jun 30, 2018 | 1.82 Bn |
| Mar 31, 2018 | 1.54 Bn |
| Dec 31, 2017 | -3.67 Bn |
| Sep 30, 2017 | 2.71 Bn |
| Jun 30, 2017 | 3.07 Bn |
| Mar 31, 2017 | 2.70 Bn |
| Dec 31, 2016 | 3.10 Bn |
| Sep 30, 2016 | 3.33 Bn |
| Jun 30, 2016 | 3.50 Bn |
| Mar 31, 2016 | 3.57 Bn |
| Dec 31, 2015 | 4.69 Bn |
| Sep 30, 2015 | 4.59 Bn |
| Jun 30, 2015 | 4.50 Bn |
| Mar 31, 2015 | 4.33 Bn |
| Dec 31, 2014 | 3.46 Bn |
| Sep 30, 2014 | 2.72 Bn |
| Jun 30, 2014 | 3.65 Bn |
| Mar 31, 2014 | 2.22 Bn |
| Dec 31, 2013 | 786.46 Mn |
| Sep 30, 2013 | 785.22 Mn |
| Jun 30, 2013 | 767.62 Mn |
| Mar 31, 2013 | 717.71 Mn |
| Dec 31, 2012 | 759.36 Mn |
| Sep 30, 2012 | 671.04 Mn |
| Jun 30, 2012 | 706.07 Mn |
| Mar 31, 2012 | 437.53 Mn |
| Dec 31, 2011 | 661.76 Mn |
| Sep 30, 2011 | 737.54 Mn |
| Jun 30, 2011 | 742.46 Mn |
| Mar 31, 2011 | 647.30 Mn |
| Dec 31, 2010 | 626.37 Mn |
| Sep 30, 2010 | 702.16 Mn |
| Jun 30, 2010 | 709.13 Mn |
| Mar 31, 2010 | 852.09 Mn |
| Dec 31, 2009 | 1.51 Bn |
| Sep 30, 2009 | 670.48 Mn |
| Jun 30, 2009 | 569.15 Mn |
| Mar 31, 2009 | 586.58 Mn |